MeiraGTx reports Q3 net loss $44.3M; Sanofi invests $30M at $7.50/share

MeiraGTx Holdings plc

2023-Q3 EPS reported -$1.91 revenue$11,977,000

Sanofi purchased $30M of ordinary shares at $7.50/share; ROFN for Riboswitch platform on CNS, I&I, metabolic targets including GLP-1 and Xerostomia.
Q3 net loss $44.3M ($0.74 per share) vs $37.3M ($0.83) prior year; license revenue $5.1M.
R&D expenses rose 65% to $27.9M driven by manufacturing costs and Janssen collaboration changes.
Cash $64.4M plus $22M Janssen receivables and $30M Sanofi investment; runway into mid-2025.
Phase 3 XLRP trial fully enrolled with IND transferred to Janssen; Phase 2 Xerostomia and Parkinson's studies ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MeiraGTx Holdings plc reported the quarter ended September 30, 2023 results: revenue $5.1 million.

Period: the quarter ended September 30, 2023
Revenue: $5.1 million
Result: reported results

Exact text from the filing

License revenue was $5.1 million for the quarter ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

MeiraGTx Holdings plc filing history →

Source: SEC EDGAR

accession 0001558370-23-018914

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.